When is the next results date for Colinz Labs?

No Upcoming Board Meetings

Who are in the management team of Colinz Labs?

As of March 2023, the management team of Colinz Labs consists of L S Mani (Director & Company Secretary), N K Menon (Whole-time Director), Vasant K Bhat (Independent Director), and A Krishna Kumar (Independent Director). They are responsible for the company's governance and operations.

As of March 2023, the management team of Colinz Labs includes the following individuals:<BR><BR>1. L S Mani - Director & Company Secretary<BR>2. N K Menon - Whole-time Director<BR>3. Vasant K Bhat - Independent Director<BR>4. A Krishna Kumar - Independent Director<BR><BR>These members play key roles in the governance and operational management of the company.

What does Colinz Labs do?

Colinz Laboratories Ltd is a pharmaceutical and biotechnology company that manufactures various pharmaceutical formulations. As of March 2025, it reported net sales of 1 Cr and a market capitalization of Rs 29 Cr.

Overview: <BR>Colinz Laboratories Ltd is a pharmaceutical and biotechnology company that manufactures a wide variety of pharmaceutical formulations.<BR><BR>History: <BR>Colinz Laboratories Ltd was incorporated as a Private Limited Company in 1986 and converted into a Public Limited Company in 1995, the same year it began its manufacturing and marketing activities. The latest quarterly results reported net sales and net profit for March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 1 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 29 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 29.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.77 <BR>Return on Equity: 5.35% <BR>Price to Book: 3.06<BR><BR>Contact Details: <BR>Address: A-101 Pratik Industrial Estate, Mulund Goregaon Link Road Mumbai Maharashtra : 400078 <BR>Tel: 91-022-25668002/8003 <BR>Email: colinzlabs@yahoo.com <BR>Website: http://www.cindoc-cll.in

Has Colinz Labs declared dividend?

No Dividend History Available

Who are the peers of the Colinz Labs?

Colinz Labs' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. While Sun Pharma and Dr Reddy's Labs show excellent management and growth, Colinz Labs has below-average growth and management risk, with a 1-year return of 66.49%.

Peers: The peers of Colinz Labs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Zenith Health, Ishita Drugs, Chemo Pharma Lab, Phaarmasia, and Desh Rakshak.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Below Average management risk is found at Colinz Labs, Zenith Health, Ishita Drugs, Phaarmasia, and Desh Rakshak. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is noted for Colinz Labs, Divi's Lab., Torrent Pharma, Zenith Health, Ishita Drugs, Phaarmasia, and Desh Rakshak. Excellent capital structure is seen at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Good capital structure is present at Colinz Labs, Torrent Pharma, and Zenith Health, and the rest have Below Average or do not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Desh Rakshak at 422.50%, while the lowest is Phaarmasia at -24.74%. Colinz Labs has a 1-year return of 66.49%, which is significantly higher than Phaarmasia but lower than Desh Rakshak. Additionally, peers with negative six-month returns include Zenith Health, Phaarmasia, and Chemo Pharma Lab.

What is the technical trend for Colinz Labs?

As of 26 May 2025, Colinz Labs shows a bullish technical trend supported by positive daily and weekly indicators, although caution is advised due to mildly bearish signals from the monthly MACD and Dow Theory.

As of 26 May 2025, the technical trend for Colinz Labs has changed from mildly bullish to bullish. The weekly MACD is bullish, supporting the upward momentum, while the daily moving averages also indicate a bullish stance. The KST is bullish on both weekly and monthly time frames, reinforcing the positive outlook. However, the monthly MACD and Dow Theory show mildly bearish signals, suggesting some caution. Overall, the current technical stance is bullish with moderate strength, driven primarily by the bullish indicators on the daily and weekly charts.

Who are the top shareholders of the Colinz Labs?

The top shareholder of Colinz Labs is Mani L S, holding 34.45% of the shares, with no pledged promoter holdings. The highest public shareholder is Dipakbhai Haribhai Gaudani at 1.31%, while individual investors collectively own 31.04%.

The top shareholders of Colinz Labs include the promoters, with Mani L S holding the largest share at 34.45%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Dipakbhai Haribhai Gaudani, who holds 1.31%. Additionally, individual investors collectively hold 31.04% of the shares.

How big is Colinz Labs?

As of 24th July, Colinz Laboratories Ltd has a market capitalization of 23.00 Cr, with recent net sales of 6.53 Cr and a net profit of 0.50 Cr. Shareholder's funds are 8.95 Cr and total assets amount to 11.36 Cr.

As of 24th July, Colinz Laboratories Ltd has a market capitalization of 23.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Colinz Laboratories Ltd reported Net Sales of 6.53 Cr and a Net Profit of 0.50 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 8.95 Cr and Total Assets of 11.36 Cr.

Should I buy, sell or hold Colinz Labs?

How has been the historical performance of Colinz Labs?

Colinz Labs has experienced a downward trend in net sales, reporting 6.53 Cr in March 2025, down from 7.03 Cr in March 2024. Despite a slight increase in profit after tax to 0.50 Cr, negative cash flow and declining revenues raise concerns about its financial stability.

Answer:<BR>The historical performance of Colinz Labs shows a fluctuating trend in net sales and profits over the years, with a slight decline in recent periods.<BR><BR>Breakdown:<BR>Colinz Labs reported net sales of 6.53 Cr in March 2025, down from 7.03 Cr in March 2024 and 7.15 Cr in March 2023, indicating a downward trend in revenue. The total operating income mirrored this decline, remaining at 6.53 Cr in March 2025. The company's total expenditure, excluding depreciation, decreased to 6.03 Cr in March 2025 from 6.49 Cr in March 2024. Operating profit (PBDIT) was 0.80 Cr in March 2025, slightly lower than 0.82 Cr in March 2024, while profit before tax was 0.62 Cr, down from 0.65 Cr the previous year. Profit after tax showed a modest increase to 0.50 Cr in March 2025 from 0.49 Cr in March 2024. The company's total assets rose to 11.82 Cr in March 2025 from 11.36 Cr in March 2024, and total liabilities also increased to 11.82 Cr from 11.36 Cr. Cash flow from operating activities turned negative at -1.00 Cr in March 2025, contrasting with a positive inflow of 1.00 Cr in March 2024. Overall, while Colinz Labs has shown some resilience in profit margins, the decline in sales and cash flow raises concerns about its financial stability.

Is Colinz Labs overvalued or undervalued?

As of November 3, 2025, Colinz Labs is overvalued with a PE ratio of 42.76 and a year-to-date decline of 35.64%, indicating a concerning long-term outlook despite a recent short-term gain.

As of 3 November 2025, Colinz Labs has moved from a fair to an expensive valuation grade. The company is currently overvalued, with a PE ratio of 42.76, an EV to EBIT of 15.61, and a ROE of 5.07%. In comparison to its peers, Sun Pharma has a PE of 35.62 and an EV to EBITDA of 24.18, while Cipla shows a more attractive PE of 22.44 and an EV to EBITDA of 5.66, highlighting Colinz Labs' relatively high valuation metrics.<BR><BR>Despite a recent uptick in stock price, with a 1-week return of 3.46% compared to a -0.94% return on the Sensex, the overall performance year-to-date shows a decline of 35.64% against a 7.47% increase in the Sensex. This suggests that while there may be short-term gains, the long-term outlook for Colinz Labs remains concerning given its current overvaluation in the context of its peers.

Are Colinz Labs latest results good or bad?

Colinz Laboratories' latest results are concerning, showing a 25.27% year-over-year decline in revenue and a sharp drop in operating margins to 5.76%, despite a slight increase in net profit. Analysts have rated the stock as a "Strong Sell," reflecting ongoing struggles with profitability and significant stock price volatility.

Colinz Laboratories' latest results indicate a challenging situation for the company. While there was a sequential improvement in net profit, which rose by 16.67% quarter-over-quarter to ₹0.14 crores, this was overshadowed by significant declines in revenue and operating margins. The company reported net sales of ₹1.39 crores for Q2 FY26, reflecting an 11.46% decrease from the previous quarter and a steep 25.27% decline year-over-year.<BR><BR>Operating margins have also compressed sharply, dropping to just 5.76%, down from 8.92% in the prior quarter and 9.14% a year ago. This margin contraction is concerning, especially as it indicates that the company is struggling to maintain profitability amid declining sales.<BR><BR>Analysts have responded to these results with a "Strong Sell" rating, highlighting the company's ongoing struggles with revenue erosion and operational inefficiencies. The stock has been volatile, trading at ₹44.90, which is significantly below its 52-week high of ₹88.70, and it has experienced a 34.16% decline over the past year.<BR><BR>Overall, the financial performance suggests that Colinz Laboratories is facing significant headwinds, making the latest results more indicative of a troubling trend rather than a positive turnaround.

Why is Colinz Labs falling/rising?

As of 14-Dec, Colinz Laboratories Ltd's stock price is rising due to strong short-term performance, gaining 9.52% over the past week and 15.00% over the last month, despite a decline in investor participation. The stock currently trades at 46.00, outperforming its sector and moving averages, indicating a positive trend.

As of 14-Dec, Colinz Laboratories Ltd's stock price is rising, currently at 46.00, with a change of 0.15 (0.33%) increase. This upward movement can be attributed to several factors. Over the past week, the stock has outperformed the benchmark Sensex, gaining 9.52% compared to the Sensex's decline of 0.52%. Additionally, the stock has shown a strong performance over the last month, with a 15.00% increase, while the Sensex has only risen by 0.95%.<BR><BR>Today, the stock has outperformed its sector by 0.28% and has been on a consecutive gain streak for the last three days, accumulating an impressive 8.31% return during this period. Furthermore, the stock's current price is higher than its 5-day, 20-day, 50-day, and 100-day moving averages, indicating a positive short-term trend, although it remains below the 200-day moving average.<BR><BR>However, it is important to note that there are signs of falling investor participation, as evidenced by a 36.41% drop in delivery volume compared to the 5-day average. Despite this, the stock remains liquid enough for trading purposes. <BR><BR>In summary, the recent rise in Colinz Laboratories Ltd's stock price is primarily driven by strong short-term performance metrics and positive returns relative to the market and sector, despite underlying long-term fundamental weaknesses.

Which are the latest news on Colinz Labs?